Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 2/20 | 0.37 |
| ▸ | CDK8 | P49336 | 2/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.34 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.34 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.34 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.34 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.34 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3225738 | 1.00 | CCNC (0.37) | CCNCCDK8HDAC3HDAC1HDAC2 | |
| SCHEMBL3226812 | 0.87 | HDAC1 (0.45) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL3226817 | 0.87 | HDAC1 (0.45) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL3226805 | 0.87 | HDAC1 (0.45) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL3234953 | 0.87 | CCNC (0.37) | CCNCCDK8HDAC3HDAC1HDAC2 | |
| SCHEMBL3234967 | 0.87 | CCNC (0.37) | CCNCCDK8HDAC3HDAC1HDAC2 | |
| SCHEMBL10069093 | 0.83 | HDAC1 (0.44) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL1972856 | 0.82 | TRPA1 (0.43) | CDK8HDAC3HDAC1HDAC2TRPA1 | |
| SCHEMBL1972858 | 0.82 | TRPA1 (0.43) | CDK8HDAC3HDAC1HDAC2TRPA1 | |
| SCHEMBL10068875 | 0.81 | TRPA1 (0.42) | HDAC3HDAC1HDAC2TRPA1TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202866-B2 | Ortho-aminoanilides for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202866-B2 | Ortho-aminoanilides for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202866-B2 | Ortho-aminoanilides for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20100069328-A1 | NOVEL ORTHO-AMINOANILIDES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE, INC. | 2010-03-18 | — | — | US | disclosed |
| US-20100069328-A1 | NOVEL ORTHO-AMINOANILIDES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE, INC. | 2010-03-18 | — | — | US | disclosed |
| US-20100069328-A1 | NOVEL ORTHO-AMINOANILIDES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE, INC. | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069328-A1 | NOVEL ORTHO-AMINOANILIDES FOR THE TREATMENT OF CANCER | IL4I1, MKI67, ABL1 | CCNC 92/4885CDK8 905/4885HDAC3 1722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.